1 study found for:    19038878 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Conditions: Hodgkin Lymphoma;   Diffuse Large B-cell Lymphoma
Interventions: Biological: campath;   Biological: Rituximab;   Drug: EPOCH

Indicates status has not been verified in more than two years